Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation

• Published in: Annals of hematology 2012-08, Vol.91 (8), p.1305-1312
• Main Authors: Taniguchi, Kyoko, Yoshihara, Satoshi, Tamaki, Hiroya, Fujimoto, Tsuguto, Ikegame, Kazuhiro, Kaida, Katsuji, Nakata, Jun, Inoue, Takayuki, Kato, Ruri, Fujioka, Tatsuya, Okada, Masaya, Soma, Toshihiro, Ogawa, Hiroyasu
• Format: Article
• Language: English
• Subjects: Adenovirus; Adenovirus Infections, Human - epidemiology; Adenovirus Infections, Human - etiology; Adenovirus Infections, Human - therapy; Adolescent; Adult; Aged; Cidofovir; Donors; Female; Haplotypes; Hematology; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic Stem Cell Transplantation - methods; Hemorrhagic cystitis; Histocompatibility - physiology; Humans; Immune reconstitution; Incidence; Infection; Lymphocytes; Male; Medicine; Medicine & Public Health; Middle Aged; Mortality; Oncology; Original Article; Pneumonia; Retrospective Studies; Risk Factors; stem cell transplantation; Tissue Donors; Transplantation, Homologous - adverse effects; Viral Load; Viremia; Young Adult
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-012-1440-3

Adenovirus (AdV) infection is an emerging complication in patients undergoing allogeneic stem cell transplantation (SCT) and is closely associated with delayed immune reconstitution. In particular, disseminated AdV disease accompanies a high mortality. We retrospectively examined the incidence of AdV infection in patients undergoing unmanipulated haploidentical SCT. Following 121 transplantations in 110 patients, three had asymptomatic AdV viremia, three had localized AdV disease (hemorrhagic cystitis, HC), and seven had disseminated AdV disease (HC + viremia). The median time from transplantation to the onset of AdV-associated HC was 15 days (range 4–39), and the median time to the onset of disseminated AdV disease was 23 days (range 7–38). The cumulative incidence of AdV-associated HC was 8.3 %, and that of disseminated AdV disease was 5.8 %. AdV group B (type 11, type 34, or type 35) was detected in plasma samples from all the patients with disseminated AdV disease. Among them, three patients who received either cidofovir or donor lymphocyte infusion (DLI) alone progressed to pneumonia and died. The remaining four patients were treated with the combination of cidofovir and low-dose unmanipulated DLI, and all survived. We showed that disseminated AdV disease is a significant complication after haplo-SCT and that the combination of cidofovir and DLI is a promising treatment option.